(0.32%) 5 116.10 points
(0.32%) 38 361 points
(0.34%) 15 982 points
(-0.94%) $83.06
(5.51%) $2.03
(0.34%) $2 355.20
(0.42%) $27.65
(4.02%) $959.20
(-0.24%) $0.932
(-0.39%) $10.98
(-0.56%) $0.796
(1.69%) $93.43
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 8.49%
@ $58.15
発行日: 15 2月 2024 @ 05:11
リターン: 1.20%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 4.68 %
Live Chart Being Loaded With Signals
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need...
Stats | |
---|---|
本日の出来高 | 51 895.00 |
平均出来高 | 370 038 |
時価総額 | 2.12B |
EPS | $-1.340 ( 2024-03-01 ) |
次の収益日 | ( $-1.310 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.32 |
ATR14 | $0.144 (0.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-23 | Seehra Jasbir | Buy | 125 000 | Employee Stock Option (right to buy) |
2024-02-13 | Seehra Jasbir | Buy | 125 000 | Employee Stock Option (right to buy) |
2024-02-13 | Regnante Keith | Buy | 40 000 | Employee Stock Option (right to buy) |
2024-02-13 | Rovaldi Christopher | Buy | 150 000 | Employee Stock Option (right to buy) |
2024-02-13 | Cooper Simon Peter | Buy | 40 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
67.66 |
Last 96 transactions |
Buy: 1 546 013 | Sell: 365 314 |
ボリューム 相関
Keros Therapeutics Inc 相関
10 最も正の相関 | |
---|---|
PRAX | 0.919 |
CDNA | 0.904 |
HNNA | 0.894 |
RPAY | 0.889 |
TTEC | 0.888 |
EWTX | 0.883 |
SMSI | 0.882 |
SRAX | 0.879 |
ANNX | 0.876 |
LPCN | 0.874 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Keros Therapeutics Inc 相関 - 通貨/商品
Keros Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $151 000 |
総利益: | $-664 000 (-439.74 %) |
EPS: | $-5.20 |
FY | 2023 |
収益: | $151 000 |
総利益: | $-664 000 (-439.74 %) |
EPS: | $-5.20 |
FY | 2022 |
収益: | $0 |
総利益: | $-1.62M (0.00 %) |
EPS: | $-4.15 |
FY | 2021 |
収益: | $20.10M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.52 |
Financial Reports:
No articles found.
Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。